Jr. John Lee Welborn - Net Worth and Insider Trading

Jr. John Lee Welborn Net Worth

The estimated net worth of Jr. John Lee Welborn is at least $335,620 dollars as of 2024-11-13. Jr. John Lee Welborn is the Director of HLS Therapeutics Inc and owns about 97,000 shares of HLS Therapeutics Inc (TSX:HLS) stock worth over $335,620. Details can be seen in Jr. John Lee Welborn's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jr. John Lee Welborn has not made any transactions after 2023-06-08 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Jr. John Lee Welborn

Jr. John Lee Welborn Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jr. John Lee Welborn owns 1 companies in total, including HLS Therapeutics Inc (TSX:HLS) .

Click here to see the complete history of Jr. John Lee Welborn’s form 4 insider trades.

Insider Ownership Summary of Jr. John Lee Welborn

Ticker	Comapny	Transaction Date	Type of Owner
TSX:HLS	HLS Therapeutics Inc	2023-06-08	Director

Jr. John Lee Welborn Latest Holdings Summary

Jr. John Lee Welborn currently owns a total of 1 stock. Jr. John Lee Welborn owns 97,000 shares of HLS Therapeutics Inc (TSX:HLS) as of June 8, 2023, with a value of $335,620.

Latest Holdings of Jr. John Lee Welborn

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
TSX:HLS	HLS Therapeutics Inc	2023-06-08	97,000	3.46	335,620

Holding Weightings of Jr. John Lee Welborn

Jr. John Lee Welborn Form 4 Trading Tracker

According to the SEC Form 4 filings, Jr. John Lee Welborn has made a total of 1 transactions in HLS Therapeutics Inc (TSX:HLS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in HLS Therapeutics Inc is the acquisition of 97,000 shares on June 8, 2023, which cost Jr. John Lee Welborn around $417,100.

Insider Trading History of Jr. John Lee Welborn

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jr. John Lee Welborn Trading Performance

GuruFocus tracks the stock performance after each of Jr. John Lee Welborn's buying transactions within different timeframes. To be detailed, the average return of stocks after 1 year bought by Jr. John Lee Welborn is -22.83%. GuruFocus also compares Jr. John Lee Welborn's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jr. John Lee Welborn within 1 year outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jr. John Lee Welborn's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jr. John Lee Welborn

Average Return

Average return per transaction

Outperforming Transactions

0 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	34.25
Relative Return to S&P 500(%)	31.8

Jr. John Lee Welborn Ownership Network

Ownership Network List of Jr. John Lee Welborn

No Data

Ownership Network Relation of Jr. John Lee Welborn

Jr. John Lee Welborn Owned Company Details

What does HLS Therapeutics Inc do?

Who are the key executives at HLS Therapeutics Inc?

Jr. John Lee Welborn is the Director of HLS Therapeutics Inc. Other key executives at HLS Therapeutics Inc include Director & Senior Officer Craig Millian , Senior Officer Brian Thomas Walsh , and 10% Security Holder Polar Asset Management Partners Inc. .

HLS Therapeutics Inc (TSX:HLS) Insider Trades Summary

Over the past 18 months, Jr. John Lee Welborn made 1 insider transaction in HLS Therapeutics Inc (TSX:HLS) with a net purchase of 97,000. Other recent insider transactions involving HLS Therapeutics Inc (TSX:HLS) include a net purchase of 20,000 shares made by Tim Hendrickson , a net purchase of 12,500 shares made by Craig Millian , and a net purchase of 32,400 shares made by Polar Asset Management Partners Inc. .

In summary, during the past 3 months, insiders sold 0 shares of HLS Therapeutics Inc (TSX:HLS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,300,000 shares of HLS Therapeutics Inc (TSX:HLS) were sold and 167,100 shares were bought by its insiders, resulting in a net sale of 1,132,900 shares.

HLS Therapeutics Inc (TSX:HLS)'s detailed insider trading history can be found in Insider Trading Tracker table.

HLS Therapeutics Inc Insider Transactions

No Available Data

Jr. John Lee Welborn Mailing Address

Above is the net worth, insider trading, and ownership report for Jr. John Lee Welborn. Currently GuruFocus does not have mailing address information for Jr. John Lee Welborn.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.